Our results and others suggest that polyP may be used in the design of therapies that replace FVIII to treat hemophilia A. In addition to the activation of VWF in primary hemostasis (this article), polyP improves secondary hemostasis in hemophilia A as well: a previous report showed that polyP reduced the clotting times [30]. The gene discussed is VWF; the disease is hemophilia A.